Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at Truist Financial

Equities researchers at Truist Financial assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued on Thursday, MarketBeat reports. The firm set a “buy” rating and a $18.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside of 119.51% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Zacks Research cut Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Jefferies Financial Group boosted their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. HC Wainwright lifted their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, B. Riley Financial boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $14.90.

Vanda Pharmaceuticals Stock Up 4.6%

VNDA stock opened at $8.20 on Thursday. The company has a market capitalization of $484.70 million, a P/E ratio of -2.20 and a beta of 0.55. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60. The firm’s fifty day simple moving average is $7.56 and its 200-day simple moving average is $5.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.17, for a total transaction of $1,276,439.95. Following the completion of the transaction, the chief executive officer owned 2,704,496 shares of the company’s stock, valued at $22,095,732.32. This represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Gunther Birznieks sold 42,431 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,904.37. Following the completion of the transaction, the senior vice president owned 494,197 shares in the company, valued at approximately $4,087,009.19. This trade represents a 7.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 314,342 shares of company stock worth $2,583,985 in the last quarter. 10.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. AIGH Capital Management LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth about $17,626,000. Millennium Management LLC raised its holdings in Vanda Pharmaceuticals by 220.0% in the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after acquiring an additional 1,470,898 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in Vanda Pharmaceuticals by 552.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock worth $6,248,000 after purchasing an additional 599,818 shares in the last quarter. Marshall Wace LLP lifted its stake in Vanda Pharmaceuticals by 945.9% in the 2nd quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock worth $2,227,000 after purchasing an additional 426,620 shares in the last quarter. Finally, Empire Financial Management Company LLC boosted its holdings in shares of Vanda Pharmaceuticals by 46.2% during the 4th quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock worth $9,775,000 after purchasing an additional 350,154 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing to review CDER’s proposed refusal to approve Vanda’s sNDA for HETLIOZ in jet lag disorder — a rare, potentially company‑moving procedural win that gives Vanda a public forum to challenge the refusal and could materially change approval odds. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ
• Positive Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 and reiterated a Buy rating with a $24 price target — a bullish analyst stance that implies significant upside vs. the current share price and may support investor interest. HC Wainwright issues estimates, Buy $24 PT
• Negative Sentiment: Multiple senior executives sold sizable blocks of stock on/around March 2 — including CEO Mihael H. Polymeropoulos (156,235 shares at ~$8.17, ~$1.28M), CFO Kevin Moran (42,442 shares at ~$8.27), SVPs and the CMO (each sold ~30k–42k shares) — collectively roughly $2.6M of disclosed insider sales and single‑digit percentage reductions in their holdings. Large, coordinated insider sales typically create near‑term selling pressure and can be perceived negatively by investors. Vanda’s Top Brass Quietly Unload a Wave of Shares
• Negative Sentiment: SEC filings disclose the individual insider trades (CEO filing available) — confirms the transactions and provides exact sizes/prices for investor review. These formal filings make the sales official and may reinforce negative market reaction while investors digest motives (tax planning, diversification, or signal). SEC filing — CEO ownership disclosure

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.